How air quality affects your sinuses and what you can do
Most people don't think about air quality until there's visible smoke on the horizon or a smog alert on the news. But your sinuses are exposed to the air around you every single hour of every day, and that constant exposure adds up. Air quality sinus issues aren't limited to wildfire smoke or heavy pollution dayseveryday particles, indoor irritants, and seasonal air changes all play a role in how congested, inflamed, or reactive your sinuses feel.
The sinuses are essentially a filtration system, and like any filter, they can become overwhelmed when the air passing through them is consistently poor. For people who already deal with allergies, chronic sinusitis, or nasal sensitivity, poor air quality often means more frequent flare-ups, longer-lasting symptoms, and a harder time finding relief with standard treatments alone.
This article breaks down exactly how air quality affects your sinuses, the difference between indoor and outdoor triggers, practical steps you can take to protect yourself, and when ongoing symptoms mean it's time to get an ENT involved rather than continuing to manage things on your own.
The air-sinus connection
How your sinuses respond to poor air quality. Your nasal passages and sinuses are lined with mucus membranes designed to trap particles, allergens, and irritants before they reach your lungs. When air quality is poor, these membranes work harder and become inflamed more easily, leading to congestion, pressure, and increased mucus production.
Why pollution and sinuses are so closely linked. Fine particulate matter (PM2.5) is small enough to penetrate deep into nasal and sinus tissue, triggering inflammation even in people without existing allergies. Repeated exposure is associated with more frequent sinus infections and heightened sensitivity to other triggers.
The compounding effect for sensitive sinuses. People with chronic sinusitis, nasal polyps, or allergic rhinitis often have sinus tissue that's already more reactive, so poor air quality doesn't just add irritation it compounds an existing inflammatory process.
Wildfire smoke, which can affect sinus health even from a distance
Pollen and mold spores, which vary by season
Ozone and smog, particularly on hot, still days
Indoor air quality concerns:
Dust mites and pet dander
Mold, particularly in humid or poorly ventilated spaces
Household chemicals and cleaning products
Poor ventilation, which lets pollutants concentrate rather than dissipate
Many people assume sinus symptoms are purely seasonal or outdoor-related, but indoor air quality can quietly sustain symptoms even when outdoor conditions improve which is why addressing both environments matters.
Check daily air quality index (AQI) reports and limit outdoor exertion on high-pollution or high-pollen days
Use a HEPA air purifier in bedrooms and main living spaces
Keep windows closed during poor air quality days and rely on filtered indoor air
Rinse sinuses with saline after outdoor exposure
Replace HVAC filters regularly, and consider higher-MERV-rated filters
Choose fragrance-free cleaning products and ensure proper ventilation
Wear a mask on high-pollution or wildfire smoke days if you have sinus sensitivity
When symptoms signal more
Occasional sinus irritation from poor air quality is common, but certain patterns suggest it's time for a specialist evaluation:
Sinus symptoms that persist for weeks rather than resolving with air quality improvements
Frequent sinus infections, especially several times a year
Chronic nasal congestion that doesn't respond to typical over-the-counter treatments
Facial pain or pressure that's persistent rather than occasional
Reduced sense of smell that lingers beyond a short-term irritation
An ENT can determine whether ongoing symptoms are primarily driven by environmental exposure, an underlying condition like chronic sinusitis or nasal polyps, or both a distinction that changes the right treatment approach, from environmental changes and allergy management to targeted treatment like allergy immunotherapy or balloon sinuplasty.
Takeaways
Air quality has a real, measurable effect on sinus health, whether from outdoor pollution, wildfire smoke, seasonal pollen, or indoor irritants that go unnoticed. For most people, a combination of monitoring air quality, improving indoor air, and using simple protective habits like saline rinses and air purifiers can meaningfully reduce symptoms.
But if sinus symptoms keep returning despite reasonable precautions, or if they're becoming more frequent and harder to manage, that's a sign the issue may go beyond air quality alone. An ENT evaluation can identify what's actually driving your symptoms and build a plan that goes further than avoidance and over-the-counter remedies.
FAQs
Can poor air quality cause sinus problems even without allergies?
Yes fine particulate matter and pollutants can irritate and inflame sinus tissue directly, even in people without a diagnosed allergy.
Is indoor air quality really as important as outdoor air quality for sinus health?
Yes, especially since most people spend far more time indoors. Indoor allergens, mold, and poor ventilation can sustain symptoms even when outdoor air is good.
How does wildfire smoke specifically affect sinus health?
It contains fine particulate matter that can travel long distances and penetrate deep into sinus tissue, triggering inflammation even far from the fire.
Do air purifiers actually make a noticeable difference for sinus symptoms?
Yes, particularly HEPA purifiers, which can meaningfully reduce indoor particulate matter and allergens.
Can air quality make chronic sinusitis worse?
Yes reactive sinus tissue can trigger more frequent or severe flare-ups compared to someone without the condition.
Should I wear a mask for sinus protection on high-pollution days?
For people with sinus sensitivity, a well-fitted mask on high-pollution or smoke days can reduce exposure and limit flare-ups.
How often should I check the air quality index (AQI)?
Checking daily, especially during allergy season or wildfire activity, helps you plan outdoor activity and take precautions early.
Can saline rinses really help after air quality exposure?
Yes they physically flush trapped particles and allergens from the nasal passages, reducing the inflammatory response.
When should sinus symptoms from air quality be evaluated by a doctor?
If symptoms persist for weeks, keep recurring, or don't improve with typical precautions, it's worth having an ENT evaluate for an underlying condition.
Are children more affected by poor air quality and sinus issues than adults?
Children can be more sensitive due to smaller airways and developing immune systems, making protective steps especially important for them.
Dr. Raj Bhayani, MD, is a board-certified ENT specialist serving Brooklyn, NY, at the New York Institute of Otolaryngology & Aesthetic Surgery. The practice provides advanced care for Chronic Sinusitis, Nasal Obstruction, Allergies, Sleep Disorders, Balloon Sinuplasty, Pediatric ENT, and Audiology with same-week appointments and minimally invasive surgical options.
Sinusitis Treatment Market to Reach USD 4.52 Billion by 2033 as Rising Chronic Sinusitis Prevalence, Biologic Therapy Adoption, and Minimally Invasive Surgical Innovation Drive Steady Global Growth
The increasing global prevalence of chronic rhinosinusitis, nasal polyposis, and allergic sinusitis — driven by rising air pollution levels, expanding allergen exposure, and growing rates of respiratory comorbidities — is generating sustained and broad-based demand for both pharmacological and surgical sinusitis treatment options. The recent clinical emergence of biologic therapies targeting Type 2 inflammation pathways in severe chronic rhinosinusitis with nasal polyps is opening a high-value new treatment category that is meaningfully expanding the sinusitis treatment market's revenue potential beyond conventional corticosteroids and antibiotics. As minimally invasive endoscopic surgical techniques become more widely adopted, drug-eluting sinus stent technology advances, and biologic treatment protocols establish themselves in specialist ENT practice, the sinusitis treatment market is entering a period of clinically and commercially compelling evolution through 2033.
HOUSTON, Texas, United States, June 2026 —
The global sinusitis treatment market size is valued at USD 2.90 billion in 2025 and is projected to grow from USD 3.07 billion in 2026 to approximately USD 4.52 billion by 2033, advancing at a CAGR of 5.7%.
The global sinusitis treatment market is undergoing a meaningful clinical and commercial transformation driven by the convergence of rising chronic sinusitis disease burden, therapeutic innovation in biologics, and continued advancement in minimally invasive surgical intervention. Sinusitis — particularly its chronic form — affects hundreds of millions of patients worldwide, imposing significant quality of life impairment, healthcare utilization burden, and lost workplace productivity that makes effective treatment both a clinical priority and a substantial commercial opportunity.
ENT pharmaceutical procurement executives, hospital surgical equipment buyers, specialty pharma strategists, respiratory therapeutics investors, and healthcare system planning leaders are all navigating a sinusitis treatment market whose competitive and clinical landscape is being reshaped by biologic innovation, device advancement, and evolving treatment pathway standards simultaneously.
What Is Driving Steady Growth Across the Sinusitis Treatment Market
The sinusitis treatment market is expanding because chronic sinusitis prevalence is rising globally, treatment-seeking behavior is increasing, and the available therapeutic toolbox is broadening — creating multiple simultaneous commercial growth levers across pharmacological, procedural, and biologic treatment categories.
Core structural demand drivers shaping the market include:
Rising global prevalence of chronic rhinosinusitis and nasal polyposis driven by increasing environmental pollution, expanding allergen sensitization, and growing rates of asthma and other respiratory comorbidities.
Growing patient awareness of chronic sinusitis as a distinct, treatable medical condition — rather than a recurring nuisance — increasing diagnosis rates and treatment-seeking behavior across both developed and emerging markets.
Expansion of biologic therapy adoption for severe, refractory chronic rhinosinusitis with nasal polyps, creating a high-value treatment category with strong clinical differentiation over conventional pharmacological options.
Increasing physician and patient preference for minimally invasive balloon sinuplasty, functional endoscopic sinus surgery, and drug-eluting sinus implant procedures over conventional open surgical approaches.
Growing use of intranasal corticosteroids, saline irrigation, and combination pharmacotherapy in primary care and ENT settings for mild-to-moderate sinusitis management.
Expanding healthcare access and ENT specialist availability in emerging markets driving diagnosis and treatment rates toward developed market levels.
North America is the dominating region in the sinusitis treatment market, driven by high chronic sinusitis diagnosis rates, well-developed ENT specialist networks, strong reimbursement coverage for both pharmacological and surgical sinusitis treatment, and the early commercial adoption of biologic therapies for refractory nasal polyposis.
Asia-Pacific is the fastest-growing region, fueled by rapidly increasing air pollution and allergen exposure in China, India, and Southeast Asia driving rising sinusitis prevalence, expanding ENT specialist capacity, growing middle-class healthcare access, and increasing adoption of advanced surgical and pharmacological sinusitis treatment options.
👃 Explore the Therapeutic Segments, Regional Growth Dynamics, and Competitive Trends Reshaping the Global Sinusitis Treatment Landscape
Access complete segment forecasts, pipeline analysis, and competitive intelligence in your complimentary sample.
Download Your Free Sample Report Now → https://www.fortunedatavista.com/sample/1122
Segment Performance Overview
The sinusitis treatment market is segmented across treatment type, disease type, distribution channel, and region — each revealing distinct clinical adoption patterns and commercial growth dynamics.
By Treatment Type:
Pharmacological treatment is the largest segment by revenue, encompassing intranasal corticosteroids, antibiotics, antihistamines, decongestants, and saline irrigation products used across acute and chronic sinusitis management.
Biologic therapies — including dupilumab and other IL-4/IL-13 and IL-5 pathway inhibitors — are the fastest-growing treatment segment, driven by expanding approval indications for severe chronic rhinosinusitis with nasal polyps and strong clinical evidence of superiority over conventional pharmacotherapy in refractory cases.
Surgical interventions including functional endoscopic sinus surgery, balloon sinuplasty, and drug-eluting sinus implant procedures represent the highest revenue-per-patient treatment segment.
Immunotherapy and allergen-specific treatment approaches are growing as allergy-driven chronic sinusitis gains clinical recognition and treatment investment.
By Disease Type:
Chronic rhinosinusitis is the largest and commercially most significant disease segment, representing the highest-cost, highest-complexity, and highest-recurrence sinusitis category driving the most pharmaceutical and surgical treatment demand.
Chronic rhinosinusitis with nasal polyps is the fastest-growing disease subsegment, as biologic therapy approvals create an expanding high-value treatment pathway for a historically difficult-to-treat patient population.
Acute sinusitis is the highest-volume disease segment by patient incidence but generates lower per-episode treatment revenue.
Allergic sinusitis is a growing segment as the link between allergic disease and chronic sinusitis receives increased clinical attention.
By Distribution Channel:
Hospital pharmacies and ENT specialist practices are the primary distribution channels for prescription pharmacological treatments and biologic therapies.
Retail pharmacies are the largest volume distribution channel for over-the-counter decongestants, antihistamines, and saline irrigation products.
Online and e-commerce channels are growing rapidly for OTC sinusitis relief products.
By End User:
Hospitals and ENT specialty clinics are the largest institutional end users, managing complex chronic sinusitis cases requiring prescription pharmacotherapy, biologic treatment, or surgical intervention.
Primary care practices are a large-volume end user for acute sinusitis antibiotic prescribing and intranasal corticosteroid prescribing.
Ambulatory surgical centers are a growing end user as minimally invasive balloon sinuplasty adoption expands beyond hospital settings.
AI Impact on the Sinusitis Treatment Market
Artificial intelligence is beginning to influence the sinusitis treatment market across diagnostic imaging, treatment planning, and drug development dimensions. AI-powered analysis of CT sinus imaging is improving the accuracy and efficiency of chronic sinusitis staging, surgical planning, and post-treatment outcome assessment — enabling ENT surgeons to make more precise, anatomy-guided decisions in functional endoscopic sinus surgery planning.
In pharmaceutical development, AI-assisted target identification and biomarker analysis tools are accelerating the identification of novel inflammatory pathway targets relevant to chronic rhinosinusitis pathophysiology — supporting the next generation of biologic and small molecule therapy development beyond currently approved IL-4/IL-13 and IL-5 pathway inhibitors.
On the clinical management side, AI-powered patient monitoring tools are being explored to track biologic therapy response, sinusitis symptom trajectory, and polyp recurrence risk in chronic rhinosinusitis patients — supporting more proactive, personalized treatment adjustment decisions between specialist office visits.
💊 Access the Full Sinusitis Treatment Market Intelligence Report — Biologics, Surgical Devices, Pharma Pipeline, and Regional Forecasts
Everything your commercial strategy and investment thesis need, in one definitive report.
Buy Now → https://www.fortunedatavista.com/checkout/1122?payment_type=single
TOC Summary — Top 10 Strategic Intelligence Points
Market sizing and revenue forecast: Detailed projections from 2026 to 2033 across treatment types, disease types, distribution channels, and regions with CAGR analysis.
Dominating region: North America leads market revenue driven by high chronic sinusitis diagnosis rates, ENT specialist density, reimbursement strength, and early biologic therapy adoption.
Fastest-growing region: Asia-Pacific is the highest-growth geography driven by rising pollution-driven sinusitis prevalence, expanding ENT capacity, and growing healthcare access across China, India, and Southeast Asia.
Treatment segment performance: Biologic therapies are the fastest-growing and highest-value treatment segment; pharmacological treatment retains the largest overall revenue share.
Disease segment trends: Chronic rhinosinusitis with nasal polyps is the most commercially dynamic disease subsegment, driven by biologic therapy expansion.
AI impact evaluation: AI is improving CT-guided surgical planning, accelerating drug discovery, and enabling personalized biologic treatment monitoring in chronic sinusitis management.
Geopolitical impact review: Drug pricing pressures, generic pharmaceutical competition from India and China, reimbursement policy differences between the U.S., EU, and Asia-Pacific markets, and regulatory approval timeline variation for biologic therapies are shaping market access and commercial strategy across regions.
Supply-demand analysis: Demand for effective chronic sinusitis treatment — particularly for refractory nasal polyposis — exceeds current treatment access in many markets, creating significant commercial opportunity for biologic therapy expansion, surgical capacity investment, and specialty pharmacotherapy access improvement.
Competitive benchmarking: Leading sinusitis treatment companies assessed on product portfolio breadth, biologic pipeline depth, surgical device capability, market access strategy, and geographic distribution reach.
Biologic therapy and pipeline trends: The expanding approval landscape for type 2 inflammation biologics and emerging pipeline compounds targeting additional sinusitis endotypes represent the most commercially significant near-term growth opportunity in the sinusitis treatment market.
Competitor Analysis:
Sanofi holds a defining commercial position in the sinusitis treatment market through Dupixent (dupilumab), the first and most commercially successful biologic therapy approved for chronic rhinosinusitis with nasal polyps. Dupixent's strong clinical evidence base, expanding approval landscape, and Sanofi's experienced specialty immunology commercial organization make it the most transformative commercial force in the sinusitis treatment pharmaceutical segment — driving the fastest-growing and highest-revenue-per-patient treatment category in the market.
Medtronic is the global leader in ENT surgical devices for sinusitis, with its Fusion ENT navigation system, balloon sinuplasty product line, PROPEL drug-eluting sinus implant technology, and NIM nerve monitoring systems representing the most comprehensive minimally invasive sinusitis surgical technology portfolio globally. Its strong ENT surgeon relationships, procedural training infrastructure, and continuous product innovation make it the dominant commercial force in the surgical sinusitis treatment segment.
Stryker competes in the sinusitis surgical device market through its ENT endoscopy, powered instrumentation, and visualization system portfolio, with particular strength in the functional endoscopic sinus surgery equipment segment. Its broad surgical device commercial reach, strong hospital relationships, and integrated ENT surgical solutions position it as a significant and commercially active competitor in the procedural sinusitis treatment market alongside Medtronic.
Geopolitical and Supply-Demand Dynamics
The sinusitis treatment market is navigating a complex commercial environment shaped by biologic drug pricing pressures, generic pharmaceutical competition, and regional reimbursement policy differences that create meaningful market access heterogeneity across geographies.
Biologic therapies for chronic rhinosinusitis with nasal polyps command premium pricing that is well-supported in the U.S. and increasingly in Western European markets but remains a significant access barrier in emerging markets and lower-income healthcare systems. Generic and biosimilar competition in intranasal corticosteroids and antibiotic pharmacotherapy is intensifying, driven by Indian and Chinese generic manufacturers, compressing margins in the largest-volume treatment segment.
On the supply-demand side, the unmet treatment need in chronic rhinosinusitis — particularly in the refractory nasal polyposis population that cycles through repeated surgical interventions and pharmacotherapy without durable disease control — is substantial and commercially significant. Biologic therapy is addressing this unmet need in patients with access, but the majority of the global chronic sinusitis population in developing markets remains underdiagnosed and undertreated, representing a large and growing addressable opportunity as healthcare access, diagnostic capability, and treatment awareness expand through 2033.
Top Key Players
Sanofi SA (France)
Medtronic plc (Ireland)
Stryker Corporation (United States)
Johnson & Johnson (Acclarent) (United States)
AstraZeneca plc (United Kingdom)
Cipla Inc. (India)
Dr. Reddy's Laboratories Ltd. (India)
Olympus Corporation (Japan)
GlaxoSmithKline plc (United Kingdom)
Teva Pharmaceutical Industries Ltd. (Israel)
Access the Full Strategic Intelligence Report on the Global Sinusitis Treatment Market
The global sinusitis treatment market size is valued at USD 2.90 billion in 2025 and is predicted to increase from USD 3.07 billion in 2026
About Us
Fortune Data Vista is a premier market intelligence and consulting company based in Texas with a branch office in India. We are known for mid and assisting firms using smart actionable data. We don't just offer surveys but we provide comprehensive strategies and professional guidance, thorough market analysis, and tailored reports to address and meet each client's factual and holistic needs.
Our research helps businesses comprehend market dynamics, assess the viability of new investments, identify growth avenues, and comprehend the market dynamics. Each report is meticulously tailored to align and target the organizational objectives while exploring new avenues in diverse international markets.
Media Contact
Fortune Data Vista
Houston Texas, United States
📞 US: +1 (917) 947-0251
📧 [email protected]
Follow Us: LinkedIn | Facebook | Twitter | YouTube
This press release is intended for business, investment, and strategy audiences seeking current intelligence on the global sinusitis treatment market.
You May Also Like:
How Will AI Impact the Future of the Sinusitis Treatment Market?
What Hidden Growth Opportunities Exist in the Sinusitis Treatment Market?
Which Segment is Generating the Highest Revenue in the Sinusitis Treatment Market?
What Competitive Strategies are Driving Success in the Sinusitis Treatment Market?
Why is the Sinusitis Treatment Market Becoming a Key Focus for Businesses?
Why ENT Surgeons Must Review Sinus CT Scans — Not Just the Report
Australia has one of the most accessible and high-quality radiology ecosystems in the world. In NSW in particular, a competitive private imaging market has delivered rapid access, excellent technology, and broad geographic coverage. For patients, this is a clear strength.
For clinicians, however, it has introduced a growing problem:
fragmentation of imaging care and over-reliance on radiology reports
These two issues intersect in a way that directly affects how we diagnose and manage sinus disease.
The Core Principle: Look at the Scan
In rhinology, one principle remains fundamental:
Always review the images—not just the report
Radiology reports almost never conclude that the sinuses are “normal.” Instead, they frequently describe:
mucosal thickening
partial opacification
retention cysts
“features of sinusitis”
For non-specialists—and for patients reading their own reports—this language implies disease. But in many cases, it does not reflect clinically meaningful pathology.
What Does “Normal” Actually Look Like?
We addressed this directly in our systematic review of sinus imaging in asymptomatic populations.
Across 16,966 individuals with no sinus symptoms, the findings were clear (1):
Mean Lund-Mackay score: 2.24
~15% had a score ≥4
13% had mucous retention cysts
17.7% had mucosal thickening ≥2 mm
The implication is straightforward:
Incidental sinus findings are common—and often normal
This is a critical point for both clinicians and patients. CT imaging is highly sensitive, but it does not distinguish between physiological variation and disease.
Simple mucosal cysts are present in 13% of all patients and thickening of mucosa of 2-4mm is common in normal asymptomatic patients.
The Clinical Disconnect
Radiologists are doing exactly what they should—describing structural findings.
But sinus disease is not defined by imaging alone.
Without this, imaging findings risk being over-interpreted.
This leads to a familiar pattern:
patients labelled with “sinusitis” based on imaging
antibiotics prescribed unnecessarily
referrals driven by reports rather than symptoms
persistent confusion when treatment fails
Why Reviewing the Images Matters
A written report cannot fully capture:
distribution of disease (localised vs diffuse)
anatomical variation
surgical relevance
correlation with symptoms
When you review the scan yourself, you can distinguish between:
mild maxillary mucosal thickening in an asymptomatic patient → likely normal
diffuse ethmoid disease with anosmia → clinically significant
This level of interpretation cannot be outsourced.
A New Problem: Fragmentation of Imaging Access
At the same time, accessing imaging has become more difficult.
Despite improved availability, we now face:
multiple radiology providers
separate portals for each group
different usernames, passwords, and 2FA systems
locked accounts from failed logins
difficulty accessing prior imaging across providers
The result is paradoxical:
More imaging—but less usable continuity
For surgeons, this affects:
comparison over time
surgical planning
confidence in decision-making
A Practical Solution: A Central Access Resource
To address this, I have created this page as a practical tool for ENT surgeons and referrers.
Instead of searching for individual radiology portals each time, you can:
select your state
choose the radiology provider
access the image portal directly
👉 Bookmark this page and use it as a central access point.
Radiology Image Access Finder
Select your state, then choose a radiology provider. The button will open the doctor / referrer image access portal.
Loading radiology access data...
State
Select state
NSW
ACT
QLD
VIC
SA
NT
TAS
WA
Radiology Group
Select radiology group
Open Doctor / Referrer Image Access Portal
This is a simple step—but one that can significantly reduce friction in daily clinical practice. Message me if there is update or correction required.
For Patients: Bring the Images
Patients should be encouraged to:
bring their imaging (USB or digital access)
use consistent providers where possible
understand that reports may not reflect disease
A report is helpful—but it is not definitive.
Listen to the Evidence
For a deeper discussion of incidental sinus findings and their clinical implications, you can listen to our podcast
OTO: Sinus Radiological Findings in General Asymptomatic Populations: A Systematic Review of Incidental Mucosal Changes
:
Conclusion
Modern rhinology requires more than access to imaging—it requires interpretation, context, and clinical judgement.
CT scans are sensitive—but not specific
Reports describe findings—but do not define disease
Access to imaging is improving—but continuity is worsening
The responsibility remains with the clinician.
If you don’t review the scan yourself, you risk treating the report—not the patient.
Reference
Razi B, Perkovic A, Alvarado R, Stroud A, Ho J, Kalish LH, Campbell RG, Sacks R, Harvey RJ. Sinus radiological findings in general asymptomatic populations: a systematic review of incidental mucosal changes. Otolaryngol Head Neck Surg. 2022;167(1):16–24.
FAQ section
Why should ENT surgeons review sinus CT images themselves?
Because radiology reports describe findings, but ENT surgeons must decide whether those findings are clinically relevant.
Are minor sinus CT abnormalities common?
Yes. Studies show that mucosal thickening, retention cysts, and low Lund-Mackay scores are common even in people without sinus symptoms.
Does mucosal thickening mean sinusitis?
Not always. Mild mucosal thickening may be incidental and must be interpreted alongside symptoms and endoscopy.
Why are prior scans important?
Prior scans allow clinicians to compare changes over time, which is often essential for diagnosis and surgical planning.
Why is radiology access difficult in Australia?
Many providers use separate portals, logins, and two-factor authentication systems, which can fragment imaging access.
If “Chronic Lungitis” Sounds Wrong, Why Do We Still Say Chronic Sinusitis?
Why “Chronic Sinusitis” and “Nasal Polyps” Are Misleading Terms
Understanding why modern rhinology is moving beyond these outdated disease labels
For decades, patients and doctors alike have used the term chronic sinusitis to describe persistent inflammation of the sinuses. It is one of the most commonly used diagnoses in ear, nose and throat (ENT) practice.
But there is a problem.
The term chronic sinusitis — or chronic rhinosinusitis (CRS) — is not actually a disease.
It is a description of inflammation, not an explanation of why that inflammation occurs.
In many ways, using the term “chronic sinusitis” today is like respiratory physicians describing asthma, COPD, bronchiectasis, and interstitial lung disease collectively as “chronic lungitis.”
No respiratory specialist would accept such a vague diagnosis. Yet in rhinology, we still routinely use a similarly imprecise term.
As our understanding of sinus disease improves, it is becoming increasingly clear that CRS is not one disease, but a group of very different conditions that share a common symptom — chronic inflammation of the sinus lining.
The Problem With the Term “Chronic Sinusitis”
The word sinusitis simply means inflammation of the sinuses.
But inflammation is a final pathway, not a diagnosis.
Inflammation can be caused by many different mechanisms:
allergy
immune dysregulation from the epithelial barrier
infection
genetic disease
mucociliary dysfunction
Grouping all of these under the same label risks oversimplifying the disease and potentially misdirecting treatment.
Nasal polyps are msimply the endpoint of chronic inflmmation and dont describe a specidfic disease condition
Historically, CRS was classified using a simple system:
CRS with nasal polyps
CRS without nasal polyps
While simple, this system ignores the biological diversity of sinus disease.
As research has advanced, it has become clear that these categories fail to reflect the underlying causes or mechanisms of inflammation.
Why “Nasal Polyps” Is Also a Misleading Diagnosis
The term nasal polyps is equally problematic.
A polyp is not a disease — it is a tissue response to chronic inflammation.
In other words, polyps are an endpoint of tissue remodeling, not the cause of the disease itself.
Many different conditions can produce tissue changes that look like nasal polyps.
These conditions have very different causes and treatments, yet they may all be described using the same label: “nasal polyps.”
Video:Polypoid degeneration of the sinus mucosa in cystic fibrosis. We understand that this condition wont respond to modern day biologics but then we dont discuss the ambiguity when treating non-CF CRS patients
This is why saying a patient “has nasal polyps” is often clinically incomplete.
It is similar to diagnosing someone with “a lung nodule” without explaining whether it is infection, inflammation, or cancer.
A Shift Toward Precision Medicine in Sinus Disease
Modern medicine is moving toward precision medicine — tailoring treatment based on the underlying mechanism of disease.
This approach has transformed the treatment of many inflammatory diseases, particularly asthma.
Asthma is no longer considered a single disease. Instead, it is divided into different endotypes, each driven by distinct inflammatory pathways.
The same shift is now occurring in rhinology.
Researchers and clinicians increasingly recognize that different forms of CRS require different treatments.
This is particularly important in the era of biologic therapies, including:
dupilumab
mepolizumab
tezepelumab
These medications target specific immune pathways and can cost tens of thousands of dollars per year.
Using them effectively requires accurate identification of the underlying disease mechanism.
The EPOS 2020 Classification of CRS
Recognising these challenges, the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS2020) proposed a more biologically meaningful classification of sinus disease.
Instead of focusing on the presence or absence of polyps, the new framework classifies primary CRS based on:
Anatomic distribution
Inflammatory endotype
This approach helps identify different clinical phenotypes that require different treatments.
Figure: Contemporary classification of primary chronic rhinosinusitis based on anatomical distribution and inflammatory endotype, adapted from EPOS2020 and Grayson et al.
Step 1: Anatomical Distribution
Primary CRS may be divided into:
Localized disease
Examples include:
isolated frontal sinusitis
isolated sphenoid sinusitis
ostiomeatal complex disease
These conditions often behave more like mechanical or obstructive diseases.
Diffuse disease
Diffuse disease involves broader inflammation across the sinus system and is typically associated with systemic inflammatory pathways.
This category includes conditions such as:
eosinophilic CRS
central compartment atopic disease
allergic fungal sinusitis
Step 2: Inflammatory Endotype
The next layer of classification focuses on the dominant immune pathway.
Two major patterns are recognised:
Type-2 (Th2) inflammation
This pathway involves cytokines such as IL-4, IL-5, and IL-13 and is associated with:
eosinophilic inflammation
asthma
nasal polyps
corticosteroid responsiveness
Many modern biologic drugs target this pathway.
Non–Type-2 inflammation
These conditions involve different immune pathways and often behave differently clinically.
Examples include:
older onset disease
smokers
corticosteroid-resistant CRS
From Classification to Real Clinical Phenotypes
When anatomical distribution and inflammatory endotype are combined, a range of distinct CRS phenotypes emerges.
Examples include:
Central compartment atopic disease (CCAD)
Eosinophilic CRS (eCRS)
Allergic fungal sinusitis (AFS)
Non-eosinophilic CRS
Each has characteristic patterns of symptoms, imaging findings, and treatment responses.
CRS is not all the same and it dictates treatment
Understanding these phenotypes allows clinicians to move beyond a simple “one size fits all” approach to sinus disease.
Why This Matters for Patients
For patients, the terminology used to describe disease can directly influence treatment decisions.
Two people diagnosed with “chronic sinusitis” may actually have completely different diseases requiring different therapies.
For example:
A patient with localized sinus obstruction may benefit primarily from surgery.
A patient with type-2 inflammatory disease may benefit from:
corticosteroids
biologic therapy
long-term inflammatory control.
Without recognising these differences, treatment can become trial-and-error.
Rethinking the Language of Sinus Disease
Medicine evolves as knowledge grows.
Just as asthma has evolved from a single diagnosis into multiple inflammatory subtypes, sinus disease is undergoing a similar transformation.
The terms “chronic sinusitis” and “nasal polyps” remain useful as broad descriptions, but they should not be considered final diagnoses.
Instead, they are starting points.
Behind those labels lies a complex group of conditions with distinct causes, biology, and treatments.
Recognising these differences is essential if we are to move toward precision medicine in rhinology.
And perhaps one day, the term chronic sinusitis will seem just as outdated as calling every lung disease “chronic lungitis.”
References
Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020.
Grayson JW, Hopkins C, Mori E, Senior B, Harvey RJ. Contemporary classification of chronic rhinosinusitis beyond polyps vs no polyps. JAMA Otolaryngol Head Neck Surg. 2020.
Grayson JW, Cavada M, Harvey RJ. Clinically relevant phenotypes in chronic rhinosinusitis. J Otolaryngol Head Neck Surg. 2019.
Frequently Asked Questions About Chronic Sinusitis
What is chronic sinusitis (CRS)?
Chronic sinusitis, also called chronic rhinosinusitis, describes persistent inflammation of the sinus lining lasting more than 12 weeks. It is not a single disease but a group of conditions with different underlying causes.
Are nasal polyps a disease?
No. Nasal polyps are not a disease themselves. They are a tissue response to chronic inflammation and can occur in many different sinus conditions.
What causes chronic sinusitis?
Many different processes can cause chronic sinus inflammation including allergy, immune dysfunction, infection, microbial imbalance, genetic diseases such as cystic fibrosis, and type-2 inflammatory conditions.
Why is CRS classification important?
Different types of CRS respond to different treatments. Understanding the underlying inflammatory pathway helps doctors choose the most effective therapy, including surgery, steroids, or biologic medications.
What is type-2 inflammation in sinus disease?
Type-2 inflammation is an immune pathway involving cytokines such as IL-4, IL-5 and IL-13. It is commonly associated with eosinophilic CRS, asthma, and nasal polyps and is the target of modern biologic therapies.
What is the EPOS classification of CRS?
The EPOS2020 guidelines classify CRS based on anatomical distribution (localized vs diffuse disease) and inflammatory endotype (type-2 vs non-type-2 inflammation).
Post by Dr Sagar Rajkuwar ENT Specialist Doctor, Nashik, India -
Are there any triggering factors for sinus headache ?
Do you often get headaches around the forehead, eyes, or nose and wonder why they keep coming back? 🤕 Many people don’t realize that common triggers like allergies, infections, weather changes, or blocked sinuses can lead to painful sinusitis headaches. Understanding the exact triggers is the first step to preventing them and finding lasting relief.
📖 Full medical explanation here: https://healthuseful.com/what-triggers-sinusitis-headaches/
Sinus Surgery and Biologics in CRSwNP: The New Goal Is Remission, Not Just Relief
Remission in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Why “Feeling Better” Is No Longer Enough
For years, success in chronic rhinosinusitis with nasal polyps (CRSwNP) meant one thing: the patient feels better.
But in 2025, that is no longer our goal.
With the arrival of biologic therapies for nasal polyps—including dupilumab, mepolizumab, and benralizumab—the target has shifted. In other airway diseases, especially asthma, the conversation has moved beyond symptom improvement toward a more ambitious endpoint: remission. Severe asthma remission has been defined as a composite state (no exacerbations, no systemic corticosteroids, sustained symptom control, stable objective measures, over time).(1) Real-world studies show that remission is achievable in a meaningful subset of biologic-treated asthma patients.(2,3)
CRSwNP shares overlapping type 2 inflammatory biology with asthma and responds to targeted biologics.(4–7) So the obvious question is:
Should we aim for remission in nasal polyps too?
The answer is yes—but CRS is structurally different.
Why Sinus Surgery Changes the Remission Conversation
Unlike asthma, we can surgically modify the anatomy in CRSwNP.
Procedures such as complete sphenoethmoidectomy and extended surgery (e.g., Draf IIc/III) reshape the inflammatory environment, improve topical access, and reduce persistent diseased compartments.(8–10) Distribution studies demonstrate that extended frontal procedures can improve irrigation penetration compared with more limited frontal approaches.(9)
Recent evidence also shows that surgical completeness predicts disease trajectory and may influence response to subsequent biologic therapy. CT-based measures of completeness such as ACCESS (Amsterdam Classification of Completeness of Endoscopic Sinus Surgery) quantify how complete surgery is and have been linked to outcomes.(11) Similarly, the Completion of Surgery Index (CoSI) provides another structured approach to capturing adequacy of surgical extent.(12)
Our recent study—Extent of sinus surgery is associated with disease control in biologic treated type-2 dominant CRS—found that extended neo-sinuis surgery was strongly associated with achieving disease control in biologic-treated patients.(13) Clincial remisison achieved in 60%+ of patients.
In other words: surgical completeness matters.
So remission in CRSwNP cannot be defined by symptoms alone.
CRSwNP Remission vs. Symptom Improvement
Traditionally, studies report:
Change in SNOT-22
Change in polyp score
Corticosteroid use
Avoidance of revision surgery
These are essential metrics and remain central in consensus guidance.(14,15) But they measure improvement, not a stable disease state.
A patient can be polyp-free yet still require repeated systemic corticosteroids. That is not remission.
That is partial control.
Partial control in nasal polyps
What Should Remission in Nasal Polyps Look Like?
A practical remission framework for CRSwNP should include multiple domains, similar to other inflammatory diseases:
